Clinical Trial

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Study acronym: Drugs-SNPs
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-09-25; most recent amendment 2026-04-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-06-23
Trial Details
NCT Number NCT06062810
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Conditions Breast Cancer
Enrollment 600 participants
Start Date 2025-06-21
Primary Completion 2026-12-18 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-23